VistaGen Unveils Rapid-Acting PH80 Nasal Spray Data for Menopausal Hot Flashes at Menopause Society Meeting
VistaGen Therapeutics Inc. presented new data on PH80, a non-hormonal nasal spray for menopausal hot flashes, at The Menopause Society 2025 Annual Meeting. PH80 shows rapid effects on autonomic activity without bloodstream absorption, hormone receptor binding, or reproductive organ impact. This supports its potential as a non-systemic treatment for menopause symptoms. The data is available on VistaGen's website. The news was originally published by VistaGen via Business Wire.
VistaGen Therapeutics Inc. has presented new exploratory data on PH80, a non-hormonal, intranasal product candidate for the treatment of menopausal hot flashes, at The Menopause Society 2025 Annual Meeting. The findings indicate that PH80 induces rapid-onset effects on physiologic markers of autonomic activity within seconds of administration and is not absorbed into the bloodstream. The research further demonstrates that PH80 does not bind to steroid hormone or neurotransmitter receptors and has no observed effects on reproductive organs in preclinical studies. These results support PH80’s potential as a rapidly-acting, non-systemic treatment option for vasomotor symptoms associated with menopause. The posters presented are available on the company’s website. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251126266096) on November 26, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
